Posted by Michael Wonder on 14 Jun 2020
Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system
12 June 2020 - The aim of this study was to evaluate the utilisation of Entresto in Ireland and compare patient characteristics to those of the pivotal PARADIGM‐HF trial.
In 2018, there were 1043 individuals receiving Entresto, corresponding to an expenditure of €1.2 million. Patients prescribed Entresto in Ireland were older, had lower left ventricular ejection fraction and were more symptomatic than those in the PARADIGM‐HF trial.
Irish patient characteristics were reflective of Entresto treated populations in other real‐world studies.
